- Previous Close
0.2330 - Open
0.2335 - Bid 0.2265 x --
- Ask 0.2340 x --
- Day's Range
0.2265 - 0.2350 - 52 Week Range
0.1992 - 0.4000 - Volume
149,670 - Avg. Volume
635,628 - Market Cap (intraday)
121.867M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date May 21, 2025 - May 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.41
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
www.vivesto.com4
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: VIVE.ST
View MorePerformance Overview: VIVE.ST
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VIVE.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VIVE.ST
View MoreValuation Measures
Market Cap
121.87M
Enterprise Value
44.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.77
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-12.82%
Return on Equity (ttm)
-22.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-39.75M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
32.29M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-32.24M